{"filing":{"accession_number":"0001193125-26-343434","cik":"0001819133","ticker":"TNGX","company_name":"Tango Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"tngx-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526343434/tngx-20260811.htm"},"events":[{"id":26866,"run_id":24434,"accession_number":"0001193125-26-343434","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Tango Therapeutics issued a press release on August 11, 2026 disclosing its financial results for the quarter ended June 30, 2026, including consolidated statements of operations and balance sheets. The filing explicitly states this is being disclosed pursuant to Item 2.02 (Results of Operations and Financial Condition), and the press release is furnished as Exhibit 99.1. This is a standard quarterly earnings release for a public company, disclosing net loss of $55.3 million for Q2 2026 and cash position of $1.0 billion, along with clinical pipeline updates and corporate milestones.","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28147,"accession_number":"0001193125-26-343434","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Tango Therapeutics issued a press release on August 11, 2026 disclosing its financial results for the quarter ended June 30, 2026, including consolidated statements of operations and balance sheets. The filing explicitly states this is being disclosed pursuant to Item 2.02 (Results of Operations and Financial Condition), and the press release is furnished as Exhibit 99.1. This is a standard quarterly earnings release for a public company, disclosing net loss of $55.3 million for Q2 2026 and cash position of $1.0 billion, along with clinical pipeline updates and corporate milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:22:38.480761+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28147,"accession_number":"0001193125-26-343434","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Tango Therapeutics issued a press release on August 11, 2026 disclosing its financial results for the quarter ended June 30, 2026, including consolidated statements of operations and balance sheets. The filing explicitly states this is being disclosed pursuant to Item 2.02 (Results of Operations and Financial Condition), and the press release is furnished as Exhibit 99.1. This is a standard quarterly earnings release for a public company, disclosing net loss of $55.3 million for Q2 2026 and cash position of $1.0 billion, along with clinical pipeline updates and corporate milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:22:38.480761+00:00","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-08-11"}]}